2025
Antidopaminergic Medications and Clinical Changes in Measures of Huntington's Disease: A Causal Analysis
Geva M, Goldberg Y, Schuring H, Tan A, Long J, Hayden M. Antidopaminergic Medications and Clinical Changes in Measures of Huntington's Disease: A Causal Analysis. Movement Disorders 2025, 40: 928-937. PMID: 40099482, PMCID: PMC12089908, DOI: 10.1002/mds.30164.Peer-Reviewed Original ResearchConceptsMeasures of clinical outcomeTotal motor scoreOutcome measuresUnified Huntington's Disease Rating ScaleHuntington's Disease Rating ScaleYears post-baselineEnroll-HD databaseFunctional outcome measuresManagement of Huntington's diseaseNew-user designAntidopaminergic medicationsHuntington's diseaseSymptom managementEnroll-HDClinical outcomesDisease Rating ScalePost-baselineMeasure of clinical progressionUnexposed cohortComposite Unified Huntington’s Disease Rating Scale,Motor scoresClinical measuresADM useAssociated with worse clinical outcomesRating Scale
2023
Association of Beta-Blocker Therapy With Cardiovascular Outcomes in Patients With Stable Ischemic Heart Disease
Godoy L, Farkouh M, Austin P, Shah B, Qiu F, Jackevicius C, Wijeysundera H, Krumholz H, Ko D. Association of Beta-Blocker Therapy With Cardiovascular Outcomes in Patients With Stable Ischemic Heart Disease. Journal Of The American College Of Cardiology 2023, 81: 2299-2311. PMID: 37316110, DOI: 10.1016/j.jacc.2023.04.021.Peer-Reviewed Original ResearchConceptsStable coronary artery diseaseCoronary artery diseaseBeta-blocker groupRecent myocardial infarctionHeart failureMyocardial infarctionCardiovascular eventsCoronary angiographyPrescription claimsObstructive coronary artery diseaseIndex coronary angiographyBeta-blocker therapyBeta-blocker useHeart failure hospitalizationElective coronary angiographyNew-user designMyocardial infarction hospitalizationsCause deathCardiovascular outcomesCause mortalityFailure hospitalizationCardioprotective benefitsArtery diseasePrimary outcomeIschemic heart
2022
Nonselective beta blockers, hepatic decompensation, and mortality in cirrhosis: A national cohort study
Serper M, Kaplan DE, Taddei TH, Tapper EB, Cohen JB, Mahmud N. Nonselective beta blockers, hepatic decompensation, and mortality in cirrhosis: A national cohort study. Hepatology 2022, 77: 489-500. PMID: 35984731, PMCID: PMC9877112, DOI: 10.1002/hep.32737.Peer-Reviewed Original ResearchConceptsNonselective beta blockersSelective beta blockersLiver-related mortalityHepatic decompensationBeta blockersCTP classPlatelet countSubgroup analysisLiver disease etiologyLower hazardNational cohort studyNew-user designInverse probability treatmentRoutine clinical settingPrior decompensationViremia statusChild-TurcotteHCV viremiaClinical confoundersComposite outcomeCohort studyPrimary outcomeActive comparatorNational cohortDecompensation
2016
Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease
Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, Grams ME. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. JAMA Internal Medicine 2016, 176: 238-246. PMID: 26752337, PMCID: PMC4772730, DOI: 10.1001/jamainternmed.2015.7193.Peer-Reviewed Original ResearchConceptsIncident chronic kidney diseaseChronic kidney diseaseGlomerular filtration rateProton pump inhibitorsPPI useAtherosclerosis RiskInhibitor useFiltration rateReplication cohortPPI usersKidney diseaseCommunity studyHigh riskIncidence of CKDPropensity score-matched nonusersProton pump inhibitor useAcute interstitial nephritisReceptor antagonist usersReceptor antagonist usePopulation-based cohortNew-user designGeisinger Health SystemAntihypertensive medicationsPPI dosingAntagonist use
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply